NAVAN
Transforming Cell Therapy Engineering
Transforming Cell Therapy Engineering
NAVAN Technologies, Inc. is a pioneering biotechnology company with the slogan "Transforming Cell Therapy Engineering". Founded in 2016 and based in the United States, NAVAN is focused on commercializing a groundbreaking non-viral delivery platform that significantly expedites genetic engineering of human stem & primary cells. The company's patented NanoStraw technology enables direct intracellular access into challenging-to-transfect stem & primary human cells for efficient delivery of various cargoes. By leveraging a physical, non-perturbative delivery mechanism, NAVAN eliminates the time, cost, and technical challenges associated with viral-based cell manufacturing, resulting in a streamlined operational process. The company secured a Seed Round investment on 25 April 2019 from notable investors including Amgen Ventures, Hemi Ventures, and HTGF | High-Tech Gruenderfonds. For more information on NAVAN, please visit www.navanbio.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 3 |
|
25 Apr 2019 |
| Grant | $750.00K | 1 |
|
08 Mar 2018 |
No recent news or press coverage available for NAVAN.
We care about your data, and we'd love to use cookies make your experience better.
